Dallas, Texas (PRWEB) November 16, 2012
This report provides an examination of the extensive portfolio of miRNA pathway drug candidates, some already in Phase II clinical trials, showing promising clinical data in different areas of medicine, such as cancer, HCV infection, and cardiovascular diseases. A focus on recent drug candidates, products, deals between different pharmaceutical companies, major participants, and new trends and developments during the last two years as well as forecasts of the future situation and major drawbacks of the miRNA drug development model and possible solutions for these obstacles, especially in context of drug stability and delivery, are covered. Additionally, identification of the main markets for RNA therapeutics and comprehensive company profiles of major players in the industry are also included in this report.
SCOPE AND FORMAT
This report is a business tool that can help market players properly evaluate new commercial opportunities in the microRNA market covering reagent, diagnostic and therapeutic submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main factors affecting each segment, and forecasts market growth, future trends, and product development in every major segment of this market.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already marketed products was conducted. These secondary sources included drug discovery and science–related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also conducted.
In a second phase, a series of semi–structured interviews was conducted with company representatives, bench scientists, marketing representatives, and other personnel at biotechnology and pharmaceutical companies. Other sources included academics, technology, and consulting companies. Subsequent analysis of the documents and interview notes was iterative.
This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment in the market for microRNA research tools, diagnostics and therapeutics. It provides insights into the market position of major companies, and shows new opportunities otherwise overlooked or less known to the business community.
Buy your copy of this report @ http://www.reportsnreports.com/reports/206072-microrna-research-tools-diagnostics-and-therapeutics-global-markets.html.
List Of Companies Mentioned In Report Include:
Antisense Pharma Gmbh
Aparna Biosciences Corp.
Applied Biological Materials Inc.
Astrazeneca Pharmaceuticals Lp
Avi Biopharma/Sarepta Therapeutics
Biocancell Therapeutics Inc.
Calando Pharmaceuticals Inc.
Cbc Comprehensive Biomarker Center Gmbh
Cenix Bioscience Gmbh
Dicerna Pharmaceuticals Inc.
Eli Lilly And Co.
Enzon Pharmaceuticals Inc.
F. Hoffman-La Roche Ag
Htg Molecular Diagnostics Inc.
Ico Therapeutics Inc.
Interna Technologies B.V.
Life Technologies Corp.
Lorus Therapeutics Inc.
Novartis International Ag
Opko Health Inc.
Phalanx Biotech Group
Quark Pharmaceuticals Inc.
Rxi Pharmaceuticals Corp.
Santaris Pharma A/S
Senesco Technologies Inc.
Tacere Therapeutics Inc.
Tekmira Pharmaceuticals Corp.
Thermo Fisher Scientific Inc.
Traversa Therapeutics Inc.
Wafergen Biosystems Inc.
Explore more reports on the Biotechnology Market @ http://www.reportsnreports.com/market-research/biotechnology/.
Contact sales(at)reportsnreports(dot)com for further information.
ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets.